MyMD Pharmaceuticals Inc Ordinary Shares MYMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MYMD is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.81
- Day Range
- $2.74–2.88
- 52-Week Range
- $2.00–70.50
- Bid/Ask
- $2.29 / $2.88
- Market Cap
- $6.13 Mil
- Volume/Avg
- 17,442 / 236,127
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.mymd.com
Comparables
Valuation
|
Metric
|
MYMD
|
AVIR
|
ITCI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.47 | 0.56 | 11.92 |
Price/Sales | — | — | 15.17 |
Price/Cash Flow | — | — | — |
Price/Earnings
MYMD
AVIR
ITCI
Financial Strength
|
Metric
|
MYMD
|
AVIR
|
ITCI
|
|---|---|---|---|
Quick Ratio | 0.99 | 17.86 | 4.95 |
Current Ratio | 1.17 | 18.24 | 5.41 |
Interest Coverage | — | — | — |
Quick Ratio
MYMD
AVIR
ITCI
Profitability
|
Metric
|
MYMD
|
AVIR
|
ITCI
|
|---|---|---|---|
Return on Assets (Normalized) | −57.97% | −15.46% | −13.47% |
Return on Equity (Normalized) | −97.86% | −16.16% | −15.88% |
Return on Invested Capital (Normalized) | −98.55% | −19.92% | −17.96% |
Return on Assets
MYMD
AVIR
ITCI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ylrvwwysz | Bcjjc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bxttkdnl | Ypgndbl | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dqpmbcnyg | Nfxlh | $97.8 Bil | |
MRNA
| Moderna Inc | Cpqmsblx | Lxgb | $41.3 Bil | |
ARGX
| argenx SE ADR | Fwfcdpf | Ykxf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ddtzgpj | Rvzr | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mxfggssz | Pplrrhf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vdzffwdrd | Grtng | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gkccfxbn | Zfsqd | $12.5 Bil | |
INCY
| Incyte Corp | Mzzqxnbc | Dkktfm | $11.6 Bil |